You are being redirected to another site.
The MDS Presidential Perspective: A New Approach to the Development of Disease-Modifying Therapies for Parkinson's Disease; Fighting Another Pandemic course focuses on discussing development of a disease modifying therapy as it is a major unmet therapeutic need in Parkinson's disease. Despite the many promising targets and candidate therapies, many pharmaceutical companies are abandoning this field because of the development costs and regulatory uncertainties. The lecture describes a new approach that Dr. Olanow believes can overcome these problems.
C. Warren Olanow MD, FRCPC, FRCP - Clintrex Research Corp, Mount Sinai School of Medicine, New York City, New York, USA
The primary purpose of this webinar is to provide information on a new approach to the development of disease-modifying therapies for Parkinson's disease
Upon completion of this activity learners will be able to:1. Be familiar with obstacles to development of a putative disease modifying therapy for Parkinson's disease2. Know the clinical designs that have been used to date to try and define a disease modifying therapy3.Appreciate a new approach to developing disease modifying therapies for Parkinson's disease
This activity is intended for movement disorder specialists, neurologists, and individuals in the biotech and pharmaceutical industry who are potentially interested in developing disease modifying therapies for Parkinson's disease
The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.
MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
